Year : 2016 | Volume
: 37 | Issue : 4 | Page : 211--213
Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
Ulrich Nitsche, Bo Kong, Alexander Balmert, Helmut Friess, Jörg Kleeff
Department of Surgery, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany
Pancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited. This article reviews stage dependent treatment options, with a special focus on the current controversy of perioperative treatment regimens in initially borderline resectable or locally advanced patients. Neoadjuvant treatment can potentially increase the rate of complete tumor resection and may be more effective than adjuvant systemic therapy. Further, in the case of disease progression during or after neoadjuvant therapy, patients can be spared extensive surgery. Today, common therapeutic regimens include gemcitabine/nab-paclitaxel and FOLFIRINOX, as well as chemoradiation. However, because of the paucity of evidence from randomized trials, most guidelines do not recommend neoadjuvant therapy in resectable tumors, and for borderline or locally advanced tumors only within clinical trials. Importantly, every patient should be discussed in multidisciplinary tumor boards.
Department of Surgery, University of Liverpool, Liverpool, UK
|How to cite this article:|
Nitsche U, Kong B, Balmert A, Friess H, Kleeff J. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?.Indian J Med Paediatr Oncol 2016;37:211-213
|How to cite this URL:|
Nitsche U, Kong B, Balmert A, Friess H, Kleeff J. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?. Indian J Med Paediatr Oncol [serial online] 2016 [cited 2017 May 23 ];37:211-213
Available from: http://www.ijmpo.org/article.asp?issn=0971-5851;year=2016;volume=37;issue=4;spage=211;epage=213;aulast=Nitsche;type=0